ScienceOpen: research and publishing network

For Researchers

Search
Advanced search

1

views

    

0

recommends

0

shares

Record: found
Abstract: found
Article: not found

The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.

Author(s): Marc L Decramer, Nicola A Hanania, Jan O Lötvall, Barbara P Yawn

Publication date: 2013

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Publisher: Dove Medical Press Ltd.

Keywords: formoterol, bronchodilator, salmeterol, LABA, COPD, indacaterol

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths.

Related collections

Author and article information

Journal

PubMed ID:: 23378756

PMC ID:: 3558319

DOI:: 10.2147/COPD.S39018

Keywords: formoterol,bronchodilator,salmeterol,LABA,COPD,indacaterol

Data availability:

Keywords: formoterol, bronchodilator, salmeterol, LABA, COPD, indacaterol

Comments

Comment on this article

scite_